By Indication

Hemophilia & Bleeding Disorders Market Analysis

Cross-industry research covering Hemophilia & Bleeding Disorders across 1 market reportspanning Pharmaceuticals & Diagnostics.

1 Reports
1 Industries

Reports Covering Hemophilia & Bleeding Disorders

Hematology Analyzers and Reagents Market to Reach USD 8.9 Billion by 2033 at 6.4% CAGR

Pharmaceuticals & Diagnostics·Market: USD 5.4 Billion (2025)·CAGR: 6.4%

Serial CBC and coagulation profiling remain standard for hemophilia management; gene therapy approvals (fidanacogene elaparvovec, NCT03861273) could gradually reduce monitoring intensity in successfully transduced patients, representing a slow but real volume headwind for this indication sub-segment.

9%

Market Share

5.5%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments